Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Inspection Overhaul Is Early Test Of US FDA’s ‘Digital Transformation’

Executive Summary

US FDA’s reorganization of its inspection office will also showcase efforts to enhance the agency’s IT infrastructure. But Commissioner Califf is warning the agency’s ‘digital transformation’ efforts could still fall victim to internal silos and external pressures to ‘divide and conquer.’

You may also be interested in...



‘Largest Reorganization In FDA’s History’: ORA Overhaul Better Thought Of As Agency-Wide Reorg

US FDA's response time and decision consistency on compliance issues should improve under reorganization that aims to take agency processes into the modern era. FDA is already moving forward on steps needed to implement the reorg as it awaits HHS and White House approval.

‘The Largest Reorganization In FDA’s History’: ORA Overhaul Better Thought Of As Agency-Wide Reorg

US FDA's response time and decision consistency on compliance issues should improve under reorganization that aims to take agency processes into the modern era. FDA is already moving forward on steps needed to implement the reorg as it awaits HHS and White House approval.

‘The Largest Reorganization In FDA’s History’: ORA Overhaul Better Thought Of As Agency-Wide Reorg

US FDA's response time and decision consistency on compliance issues should improve under reorganization that aims to take agency processes into the modern era. FDA is already moving forward on steps needed to implement the reorg as it awaits HHS and White House approval.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS149518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel